Skip to main content

Resource Library

Newsletter icon

May 17, 2018

Illicit Opioids: Office of National Drug Control Policy and Other Agencies Need to Better Assess Strategic Efforts

As Congress considered a bill to reauthorize the Office of National Drug Control Policy (ONDCP), the U.S. Government Accountability Office was asked to discuss in testimony before the Committee on Oversight and Government Reform, House of Representatives, federal agencies' specific opioid-related strategies and the extent to which each agency is measuring its performance, as well as federal agencies' efforts to enhance collaboration and information sharing to limit the availability of illicit opioids, ongoing challenges to doing so, and ONDCP's role in enhancing such collaboration.

Pick Your Pathway Pathway